{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:16:37Z","timestamp":1761855397210,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virus Eradication"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jve.2021.100030","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T21:30:39Z","timestamp":1612560639000},"page":"100030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Commentary title: COVID-19 research, Africa, and global health"],"prefix":"10.1016","volume":"7","author":[{"given":"Tinkhani","family":"Mbichila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ntando","family":"Yola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quarraisha Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Tchelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regine","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jve.2021.100030_bib1","series-title":"COVID-19 Weekly Epidemiological Update","first-page":"4","author":"World Health Organization","year":"2020"},{"issue":"6505","key":"10.1016\/j.jve.2021.100030_bib2","first-page":"756","article-title":"Africa\u2019s pandemic puzzle: why so few cases and deaths?","volume":"369","author":"Nordling","year":"2020","journal-title":"Am. Assoc. Adv. Sci."},{"issue":"24","key":"10.1016\/j.jve.2021.100030_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMc2014960","article-title":"The South African response to the pandemic","volume":"382","author":"Abdool Karim","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jve.2021.100030_bib4","article-title":"COVID-19 trials at risk after Africa \u2018racism\u2019 backlash - SciDev","author":"William","year":"2020","journal-title":"Net. Sci Dev Net"},{"author":"Associated Press","key":"10.1016\/j.jve.2021.100030_bib5"},{"issue":"6494","key":"10.1016\/j.jve.2021.100030_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1126\/science.abc9528","article-title":"COVID-19 research in Africa","volume":"368","author":"Bekker","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jve.2021.100030_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0147743","article-title":"Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-Saharan Africa","volume":"11","author":"Nel","year":"2016","journal-title":"PloS One"},{"issue":"22","key":"10.1016\/j.jve.2021.100030_bib10","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jve.2021.100030_bib11","doi-asserted-by":"crossref","unstructured":"Bockarie MJ. How Africa has developed its scientific research capabilities. Conversat. April 8, 2020;.","DOI":"10.64628\/AAJ.jfwkjc7hs"},{"key":"10.1016\/j.jve.2021.100030_bib13","first-page":"e1","article-title":"Building trust in COVID-19 vaccines and beyond through authentic community investment","author":"Ojikutu","year":"2020","journal-title":"Am J Publ Health"},{"issue":"4","key":"10.1016\/j.jve.2021.100030_bib14","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2589-7500(20)30027-3","article-title":"Sub-Saharan Africa\u2014the new breeding ground for global digital health","volume":"2","author":"Holst","year":"2020","journal-title":"Lancet Digit. Heal."},{"key":"10.1016\/j.jve.2021.100030_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/d41586-020-01265-0","article-title":"Let Africa into the market for COVID-19 diagnostics","volume":"580","author":"Nkengasong","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jve.2021.100030_bib16","first-page":"5","article-title":"Advancing equitable global health research partnerships in Africa","volume":"3","author":"Boum","year":"2018","journal-title":"BMJ Glob. Heal."},{"key":"10.1016\/j.jve.2021.100030_bib17","first-page":"21","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: a phase 2 HIV pre-exposure prophylaxis study in women","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"24","key":"10.1016\/j.jve.2021.100030_bib18","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A\u00a0randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jve.2021.100030_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1812281","article-title":"Universal testing, expanded treatment, and incidence of HIV infection in Botswana","volume":"381","author":"Makhema","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.jve.2021.100030_bib20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","article-title":"Ebola RNA persistence in semen of ebola virus disease survivors \u2014 final report","volume":"377","author":"Deen","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jve.2021.100030_bib21","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1016\/S2352-3018(17)30156-X","article-title":"Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067\/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"issue":"16","key":"10.1016\/j.jve.2021.100030_bib22","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5996","key":"10.1016\/j.jve.2021.100030_bib23","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Karim","year":"2011","journal-title":"Science (80-. )"},{"issue":"10","key":"10.1016\/j.jve.2021.100030_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1473-3099(16)30020-2","article-title":"Comparison of artesunate\u2013mefloquine and artemether\u2013lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial","volume":"16","author":"Sirima","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jve.2021.100030_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jve.2021.100030_bib26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jve.2021.100030_bib27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1371\/journal.pmed.0020298","article-title":"Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial","volume":"2","author":"Auvert","year":"2005","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.jve.2021.100030_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"issue":"10068","key":"10.1016\/j.jve.2021.100030_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jve.2021.100030_bib30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A\u00a0trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jve.2021.100030_bib31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa0907847","article-title":"Rapid molecular detection of tuberculosis and RIfampicin resistance","volume":"363","author":"Boehme","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Virus Eradication"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664021000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2055664021000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:10:54Z","timestamp":1761855054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2055664021000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2055664021000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jve.2021.100030","relation":{},"ISSN":["2055-6640"],"issn-type":[{"type":"print","value":"2055-6640"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary title: COVID-19 research, Africa, and global health","name":"articletitle","label":"Article Title"},{"value":"Journal of Virus Eradication","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jve.2021.100030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100030"}}